Danaher Corp. (0R2B)
London Exchange · UK · prices in USD · close of 20 Oct 2026
Key indicators
| Last close | USD 224.73 |
|---|---|
| 52-week range | 159.95 – 244.50 |
| Return, 1 month / 3 months | +4.9% / +17.5% |
| Return, 1 year / 3 years | +2.8% / +5.0% |
| Trend | Uptrend |
| RSI (14) | 56 |
| Volatility (1 year) | 29.4% |
| Worst drawdown (1 year) | -33.0% |
| Average daily value traded | 1.01M USD |
| Dividend yield | 0.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Danaher is a science and technology company based in Washington, D.C. that serves customers in the life sciences, diagnostics and biotechnology fields. Its businesses supply laboratory instruments, diagnostic testing systems, microscopy equipment and bioprocessing tools used by researchers, hospitals and pharmaceutical manufacturers. Danaher's products help scientists study cells, analyse samples and produce biological medicines, and its customers include healthcare providers, academic laboratories and industrial companies around the world.
The shares are listed on the London Exchange in UK under the code 0R2B, and the price on this page is in US dollars (USD). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Danaher Corp. (0R2B) trades on the London Exchange in UK. It last closed at USD 224.73 on 20 October 2026.
Its price-based Market X-Ray is 61 out of 100 (a fair price profile), ranking 1,197 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 2.8% and over the last three months it rose 17.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 75 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 12.0% | ||
| From 52-week high | -6.9% | ||
| Momentum | 71 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 17.5% | ||
| 6-month return | 26.0% | ||
| 12-month return, skipping the last month | -2.0% | ||
| Stability (higher is calmer) | 53 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 29.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -33.0% | ||
| Liquidity | 53 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.01M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 38 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.1% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | −0.3% |
|---|---|
| 1 month | +4.9% |
| 3 months | +17.5% |
| 6 months | +26.0% |
| 1 year | +2.8% |
| 3 years | +5.0% |
| 5 years | – |
Signals
| 50-day / 200-day average | 214.79 / 200.68 |
|---|---|
| Golden / death cross (60 days) | Golden, 29 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 8.03 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 24 Dec 2025 | USD 0.3200 |
| 25 Sep 2025 | USD 0.3200 |
| 26 Jun 2025 | USD 0.3200 |
| 27 Mar 2025 | USD 0.3200 |
| 27 Dec 2024 | USD 0.2700 |
| 26 Sep 2024 | USD 0.2700 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.